The latest clinical trial results for lenacapavir have shown it to be 96% effective in preventing HIV infections, resulting in optimism about potentially ending the epidemic.
In a significant trial, PURPOSE 2, lenacapavir demonstrated a 96% efficacy in a diverse group of over 3,200 individuals, showcasing its potential to eliminate new infections.
Ethel Weld from Johns Hopkins described the lenacapavir results as a thrilling game changer for HIV prevention, emphasizing its promise as an alternative to daily PrEP.
The 100% efficacy seen in the previous lenacapavir trial with cisgender women highlights the drug's potential and adds enthusiasm towards the goal of eradicating HIV.
Collection
[
|
...
]